MedTrace Logo

Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects

NCT03835637 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-02-08

No results posted yet for this study

Summary

This is a single centre, open-label, non-randomised study with up to 2 parts, assessing the safety, tolerability, PK and PD of single (Part A) and multiple (Part B; optional) doses of oral GR antagonist ORIC-101.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ORIC-101

Capsule or oral suspension

Sponsors & Collaborators

  • ORIC Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-23
Primary Completion
2018-07-04
Completion
2018-07-04

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03835637 on ClinicalTrials.gov